Cirrhosis and liver cancer are major causes of morbidity and mortality. Worldwide, most cases of cirrhosis and liver cancer are caused by chronic infection with hepatitis B (HBV) or C viruses (HCV).
1,2 Unfortunately, despite effective vaccination for hepatitis B and improvements in antiviral therapies for both hepatitis B and hepatitis C, the global burden of chronic hepatitis B and/or hepatitis C infection and virally mediated liver disease remains enormous. 2, 3 Progressive liver damage from chronic HBV/HCV occurs because chronic viral infection increases the death rate of hepatocytes. 4 This triggers repair responses to replace the cells that died. 4 In some individuals, however, repair is fibrogenic and results in progressive accumulation of collagen matrix. 5 Fibrogenic repair is also generally accompanied by vascular remodeling and hepatic accumulation of liver progenitor cells. 5 Expansion of liver progenitor populations, in turn, provides a source of immature cells with survival advantages, some of which may eventually become tumorinitiating cells for primary liver cancers. 6 Primary hepatocellular carcinoma (HCC) is a major cause of liverrelated death in HBV/HCV-infected individuals with cirrhosis. 3, 4 Therefore, fibrogenic repair contributes to the pathogenesis of the potentially fatal outcomes of chronic viral hepatitis. Recent studies of cultured cells, animal models of metabolic and biliary types of liver disease, and small numbers of liver biopsy samples from patients with similar conditions have identified a mechanism that modulates fibrogenic repair, namely, activation of the Hedgehog (Hh) signaling pathway. [7] [8] [9] Hh ligands are morphogens that orchestrate tissue construction and remodeling by initiating autocrine and paracrine signaling in Hh-responsive cells. 10 In such cells, interaction of Hh ligands with Patched (Ptc) receptors on the cell surface releases the signaling-competent co-receptor, Smoothened (Smo), from Ptc repression. This permits intracellular signal transduction that culminates in the nuclear localization of Glioma-associated oncogene family transcription factors (Gli1, 2, and 3) that regulate the transcription of Hh-responsive genes. 10 Hepatic stellate cells (HSCs), some cholangiocytes, liver progenitors, and lymphocytes are capable of producing Hh ligands. 8, [11] [12] [13] Hh ligands function as viability factors for multipotent progenitors that are capable of differentiating into mature hepatocytes or cholangiocytes. 11 They also stimulate quiescent HSCs to acquire a more myofibroblastic phenotype, and promote the proliferation and survival of myofibroblastic cells. 13 In addition, Hh ligands act in a paracrine fashion to induce cultured ductular cells to undergo epithelial-to-mesenchymal transition (EMT), providing another mechanism that might increase myofibroblastic cell numbers in livers. 8, 14, 15 In vitro, myofibroblast-derived Hh ligands upregulate expression of various chemokines and chemokine receptors in neighboring immature liver epithelial cells, facilitating hepatic recruitment and retention of certain types of immune cells. 16 Some of these immune cells, in turn, produce and respond to Hh ligands, 12, 16 further enriching the microenvironment with morphogens. Finally, Hh ligands may influence vascular remodeling during liver damage because they exert pro-angiogenic effects during development and adult wound healing responses. 17, 18 Indeed, liver sinusoidal endothelial cells (SECs) were recently shown to be Hh-responsive cells that upregulate their expression of adhesion molecules and other markers of activated sinusoidal endothelium when exposed to Hh ligands. 19 Hence, there is growing experimental evidence that Hh signaling increases during liver injury and that activation of the Hh pathway promotes many processes that are known to occur during fibrogenic liver repair, including growth of myofibroblastic populations, EMT, vascular remodeling, and hepatic accumulation of inflammatory cells and liver progenitors.
Whether or not the Hh pathway modulates the outcomes of virally mediated liver injury has never been examined. Recent gene-profiling studies of human liver cancer repositories provide evidence for Hh pathway activation in a substantial proportion of HBV/HCV-related HCCs. [20] [21] [22] Given that virally induced cirrhosis is a strong risk factor for HCC, the latter data suggest that Hh pathway activation might occur during chronic viral hepatitis. If verified, this raises additional questions about the role(s) of Hh-responsive cells in regulating disease progression and hepatocarcinogenesis during virally mediated liver disease. The goals of this study, therefore, were to determine if the Hh pathway becomes activated in the livers of patients with chronic viral hepatitis; to characterize the types of liver cells that produce and/or respond to Hh ligands in virus-infected livers; and to delineate potential mechanisms by which Hh signaling might contribute to fibrotic repair and hepatocarcinogenesis in this context. We hypothesized that Hh signaling would increase in cell populations that mediate fibrogenic repair during chronic viral hepatitis and induce such cells to acquire phenotypes that promote liver fibrosis, vascular remodeling, and hepatocarcinogenesis. Hence, fibrosis stage and HCC development were predicted to increase in parallel with the level of Hh pathway activity in patients with chronic viral hepatitis.
MATERIALS AND METHODS Human Samples
A total of 45 formalin-fixed paraffin-embedded (FFPE) liver biopsies from subjects with progressive hepatitis B (n ¼ 23) and C (n ¼ 22) were obtained from the Department of Pathology tissue repository at Universidade Federal do Espírito Santo, Brazil (see details in Supplementary Materials and Methods). The demographic data of selected subjects are described in Table 1 . FFPE liver sections were also obtained from residual healthy liver tissues of two donor livers that were utilized for split liver transplantation at Duke University Hospital. The study was approved by the human ethics committee of Centro de Ciências da Saú de, Universidade Federal do Espírito Santo (033-09) and by the Duke institutional review board, and it fulfilled Institutional and NIH Guidelines for human subject research.
Histology and Immunohistochemistry (IHC) FFPE livers were prepared for IHC and serial sections were stained with H&E and Sirius red. For each immunostain, sections from control livers and sections from livers with viral hepatitis were always processed identically and concurrently. Each assay also always included appropriate positive controls (other types of diseased human liver with known Hh pathway activation) and negative controls (diseased human liver incubated with secondary antibody but without primary antibody). Detailed protocols are in Supplementary Materials and Methods and antibodies used are listed in Supplementary Table 1 .
Cell Lines and Studies to Assess Effects of Viral Proteins on Hh Ligand Production Huh-7 cells (gift from Eckard Wimmer, Stony Brook University, NY, USA) were grown according to standard protocols. 23 After pilot experiments were completed to establish optimal conditions for viral infection, Huh-7 cells were infected with HCV genotype 2a JFH-1 virus (MOI of 0.1) 24, 25 or control adenoviral vectors (gift from P Goldschmidt-Clermont, University of Miami, FL, USA; MOI of 50) 26 and harvested 72 h later for RNA isolation/analysis.
Isolation and Culture of Human Primary HSCs and SECs to Assess Effects of Hh Pathway Activity
Approximately 25 g of finely cut liver obtained from a residual segment of healthy human liver was used for primary isolation of HSCs and SECs as previously described. 27, 28 To assess the effects of Hh pathway activity, primary HSCs and SECs were treated with cyclopamine (5 mM, Toronto Research Chemicals, Toronto, Canada), an inhibitor of Hh signaling, or its catalytically inactive analog, tomatidine (5 mM). 29 RNA and protein were harvested for qRT-PCR and western blot analysis 48 h later.
Angiogenesis Assay
A total of 12 000 primary human SECs (from ScienceCell, San Diego, CA, USA) were seeded in each well of chamber slide with 100 ml Matrigel after 30 min of reincubation at 37 1C. 30 Wells were photographed at different time points at random fields with the use of a confocal microscope (Zeiss LSM Pascal Axiovert; Carl Zeiss, Welwyn Garden City, Hertfordshire, UK). The length of the vascular tubes after 16 h was digitally analyzed using AnalySISD software (Olympus Biosystems, Münster, Germany). Cultures were treated with vehicle, recombinant sonic hedgehog (Shh; 5 mg/ml; Stem Cell Tech, Vancouver, Canada), primary HSC (from ScienceCell) conditioned medium with or without cyclopamine, or pre-treated with short hairpin RNAs (shRNAs) targeted against Smo to determine effects on tube formation, a wellcharacterized surrogate for angiogenesis. 30 shRNA was designed as previously described; 31 Smo shRNA sequence is shown in Supplementary RNA Isolation from FFPE Tissue and qRT-PCR Total RNA was isolated from archival FFPE tissue using RNeasy FFPE kit (Qiagen, Valencia, CA, USA) following the manufacturer's protocols. As the concentration of obtained cDNA was very low, qRT-PCR cycles were increased to 50 (60 for Laser Capture samples), and all work involving mixing of reagents and loading of plates was performed in a sterile hood to prevent contamination.
For laser capture microdissection (LCM) Palm MicroBeam Microlaser and Zeiss microscope were used. First, FFPE tissue was deparaffinized in xylene for 5 min and was then cut using Auto-LPC option that allows catapulting of selected tissue parts into collection vessel. Following tissue collection, RNA was isolated using RNeasy FFPE kit. Final cDNA was diluted to 50 ml, and 5 ml was used per reaction.
Statistical Analysis
Results are expressed as means±s.e.m. Comparisons between groups were performed using the nonparametric Wilcoxon Table 1 The demographic data of the selected patients from whom the tissue was used for the study Hedgehog signaling in hepatitis B and C T de Almeida Pereira et al rank-sum test using SAS version 9.1 software (SAS Institute, Cary, NC, USA). The P-values are two tailed; significance was accepted at the 5% level.
RESULTS

Patient Populations
In all, 22 patients with liver disease caused by chronic HBV infection and 23 patients with chronic HCV-induced liver disease underwent clinically indicated liver biopsies, and residual, de-identified FFPE tissues were used for this study. Table 1 summarizes the clinical information that was submitted with each liver biopsy. Males predominated in the subgroups with HBV and HCC. Patients tended to be middle aged. However, the group without cancer was generally about one decade younger than the group with coincident HCC. Serum aminotransferase values were less than two-fold elevated in patients with chronic HBV, including the subgroups with advanced fibrosis and/or HCC. HCV patients who had no fibrosis (F0) or only mild-moderate fibrosis (F1/F2) also had relatively normal serum aminotransferases, whereas HCV patients with F3/F4 fibrosis and/or HCC had significant aminotransferase elevations. (Figure 3b ). These findings suggested that the myofibroblast population was enriched with Hh-responsive cells.
Chronic Viral Hepatitis Increases Hepatic Production of Hh Ligands
To more directly examine the potential significance of Hh signaling in myofibroblastic liver cells, HSCs were isolated from residual healthy liver allograft tissue, and cultured to induce myofibroblastic transdifferentiation. Myofibroblastic human HSCs were then treated with cyclopamine, a highly specific Hh signaling antagonist, or its biologically inactive analog, tomatidine. Primary myofibroblastic HSCs that were treated with tomatidine demonstrated Hh pathway activation, as evidenced by expression of Hh target genes (Gli2), as well as the expected production of various myofibroblast markers, such as a-sma and collagen 1a1 (Col1a1; Figure 3c and d). In contrast, treating myofibroblastic HSCs with cyclopamine inhibited Hh signaling and significantly repressed expression of myofibroblast-related genes ( Figure  3c and d) . These in vitro data complement the findings in whole liver tissue, and suggest that the Hh pathway has an important role in maintaining the myofibroblastic phenotype of stromal cells that accumulate during the progression of chronic viral hepatitis.
Hh Ligands Increase Expression of Activation Markers in Human Hepatic SECs and Promote Angiogenesis
Further inspection of the fibrous septae in immunostained sections of HBV-or HCV-infected livers with advanced fibrosis demonstrated Ptc-expressing cells and cells with Gli2-positive nuclei lining apparent vascular spaces (Supplementary Figure 6A and B). Strong expression of CD31, a marker of activated SECs, was also noted in these areas (Supplementary Figure 6C ). In order to determine if the activated endothelial cells were Hh responsive, additional sections were double stained for CD31 and Gli2. Many cells that lined vascular spaces within fibrous septae coexpressed CD31 and Gli2 in livers with chronic viral hepatitis, indicating that activated hepatic endothelial cells are Hh responsive (Figure 4a ).
To more directly assess the role of Hh signaling in hepatic vascular remodeling, primary endothelial cells were isolated from residual human liver allograft tissue from a healthy donor, placed in culture to induce activation, and then treated with cyclopamine or tomatidine. Culture-activated endothelial cells exhibited evidence of Hh pathway activation (increase in Gli2 mRNA level); cyclopamine treatment inhibited Hh signaling and repressed endothelial cell gene expression of the activation marker CD31 (Figure 4b) . In separate experiments, human SECs were cultured in matrigel and Hh signaling was manipulated to determine effects on vascular tube formation. In this angiogenesis model, treatment with recombinant Shh or myofibroblast-conditioned medium (a source of Hh ligands) stimulated tube formation, whereas various strategies that inhibited Hh signaling blocked tube formation (Figure 4c Figure 7) , demonstrating that many epithelial cells in the ductular reaction were producing and responding to Hh ligands. Autocrine Hh signaling is a general property of progenitor cells.
11,32 Therefore, we used IHC to assess progenitor markers in the ductular cells of the virally infected livers. The results indicate that such cells generally express several wellaccepted markers of liver epithelial progenitors, including Krt7 ( Figure 5c ) and CD133 (Figure 5d ). Interestingly, many of these cells also stained positively for typical mesenchymal markers, such as a-SMA (Figure 5e ) and S100A4 (Figure 5f ). Coexpression of epithelial and mesenchymal genes is an accepted characteristic of cells that are undergoing EMT. 14, 33 Thus, the new results support earlier work that showed that Hh pathway activation induced EMT in immature ductular cells, 8 and demonstrate that livers with chronic viral hepatitis become enriched with populations of Hh-responsive progenitors that are undergoing EMT. 
Hh-Responsive Cells Are Particularly Enriched in Peritumoral Stroma of HCCs
Because chronic viral hepatitis is a major risk factor for HCC, 2, 3 and Hh pathway activation has been demonstrated in certain HCC cell lines, 21 we used IHC to localize Hh ligand-producing cells and Hh-responsive cells in livers with chronic viral hepatitis and co-incident HCC. To our surprise, we were generally unable to demonstrate Shh, Ihh, Ptc, or Gli2 staining in malignant hepatocytes. However, the peritumoral stromal tissue was enriched with cells that expressed Ptc and S100A4. LCM and qRT-PCR analysis revealed robust expression of Ptc mRNA in the fibrous tissue that Hedgehog signaling in hepatitis B and C T de Almeida Pereira et al surrounded tumor nodules ( Figure 6 ). Closer inspection revealed that this fibrous tissue was riddled with vascular spaces and enriched with poorly formed ductular structures. IHC demonstrated that fibrous tissue adjacent to tumors harbored numerous ductular structures that expressed Shh and Gli2, as well as stromal cells that expressed Ihh, Gli2 (Figure 7a and c) and/or Ptc (Supplementary Figure 7B) .
Further immunostaining demonstrated that these ductular structures tended to express Krt7, a marker of immature liver epithelial cells (Figure 7d and Supplementary Figure 7C) ; most also stained positively for the tumor stem/progenitor markers CD133, EpCam (Figure 7e and f) , and survivin (Supplementary Figure 7D) . Malignant hepatocytes along the edge of this peritumoral stroma also expressed EpCam and Hedgehog signaling in hepatitis B and C T de Almeida Pereira et al
DISCUSSION
Chronic infection with HBV and HCV is a major cause of cirrhosis and liver cancer worldwide. 2, 3 Nevertheless, many individuals do not develop significant liver fibrosis or neoplasia, 3, 4 and although there is little argument that viral infection increases hepatocyte death, viral levels do not reliably predict important outcomes of liver injury. At present, the mechanisms that account for the variable consequences of chronic viral hepatitis are not fully understood.
We performed a cross-sectional analysis of liver biopsy samples from patients with chronic HBV or chronic HCV and with differing degrees of liver fibrosis. A subgroup of the patients had co-incident HCC. Our results suggest that interindividual differences in the degree of Hh pathway activation that occur during chronic viral infection may mediate some of the variability in viral hepatitis outcomes. We found that chronic infection with hepatitis viruses significantly increased hepatic expression of Hh ligands (Shh and Ihh) and target genes (Ptc and Gli2), and noted that individuals with more advanced stages of liver disease (ie, bridging fibrosis to cirrhosis) expressed higher levels of Shh, Ptc, and Gli2 than those with little or no fibrosis. In our study population, all of the HCCs occurred in livers with advanced fibrosis/cirrhosis; cirrhotic livers also tended to have the greatest net Hh pathway activity. Thus, higher levels of Hh pathway activity associated with both of the potentially fatal outcomes of chronic viral hepatitis (ie, cirrhosis and primary liver cancer).
The design of our study (retrospective, cross-sectional analysis) and nature of our study population (humans) prevented us from manipulating Hh signaling to test the potential cause-effect relationship between Hh pathway activity and outcomes of advanced virus-mediated liver disease in our study cohort. However, to overcome this limitation, we performed IHC to characterize the types of liver cells that produced and responded to Hh ligands in our patients, and then used cultured human liver cells to determine if (and how) manipulating Hh signaling altered the phenotypes of the relevant Hh-responsive cells.
IHC revealed that liver epithelial cells (ie, hepatocytes and ductular cells) were the major source of Shh ligands in patients with viral hepatitis, whereas stromal cells were the predominant producers of Ihh ligands in these subjects. Introducing HCV proteins into cultured liver epithelial cells induced significant expression of Shh mRNA but had no appreciable effect on Ihh expression. To our knowledge, these data provide the first evidence that hepatitis-viral infection of liver epithelial cells stimulates such cells to produce Shh ligand, a potent morphogen and viability factor for various stem/progenitor cells.
Immunostaining also demonstrated that the major liver cell populations that typically expand during cirrhosis (ie, myofibroblasts, activated SEC, and liver epithelial progenitors) are all enriched with cells that respond to Hh ligands. Treating cultures of primary human myofibroblastic HSCs
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Gli-2 K7 CD133 αSMA S100A4 Hedgehog signaling in hepatitis B and C T de Almeida Pereira et al levels of fibrosis, vascular remodeling, and progenitor accumulation that ensue. Many types of adult cancers, including HCCs, exhibit aberrant activation of the Hh pathway. 20, 21, 34 We were unable to demonstrate Hh ligand or target gene expression within nodules of HCCs in livers with chronic viral hepatitis, but noted striking enrichment of peritumoral stromal tissue with a spectrum of cells that produced and/or responded to Hh ligands, ranging from ductular-appearing cells to fibroblastic cells. Moreover, some of these peritumoral cells coexpressed markers of cancer stem/initiating cells and mesenchymal cells. Coexpression of epithelial and mesenchymal genes is a characteristic of cells that are undergoing EMT/MET. 14, 33 Hence, these findings suggest that 'epithelioid' nodules of HCCs were derived from subpopulations of malignantly transformed, Hh-responsive liver progenitors. Such tumor stem/initiating cells have relatively mesenchymal phenotypes, and seem to reside in peritumoral stroma until Hh signaling is repressed sufficiently to permit them to undergo MET, whereby they progressively acquire more hepatocytic features. Additional research is necessary to prove/disprove this concept. However, it is consistent with the known ability of Hh ligands to promote EMT, 8, 10 the fact that HCC cell lines display variable levels of Hh pathway activity and mesenchymal gene expression, 35 evidence that viral factors induce EMT in liver cells, 36, 37 and findings of EMT-related gene expression in HCV-related HCC. 15, 38 Therefore, like cirrhosis, HCC may be a direct consequence of Hh-dependent remodeling of liver damage caused by chronic viral infection. If confirmed, such results would have important implications for patients with viral hepatitis because (1) interindividual differences in Hh responsiveness may underlie observed differences in the outcomes of chronic HBV/HCV and (2) Hh inhibitors may help to prevent cirrhosis and HCC in patients with these diseases.
